Shalina Healthcare

Rufenac

Rufenac is used in the treatment of pain and inflammation of various origins

• Tablets

Indications

Pain and inflammation of various origins. Chronic inflammatory rheumatism, painful and disabling arthritic pain (long-term symptomatic treatment)

Pharmacological Class

Phenyl-acetic acid derivative non-steroidal anti-inflammatory

Pharmacological Properties

Anti-inflammatory, analgesic

Mechanism of Action

• Non-steroidal anti-inflammatories (NSAIDs) exert a potent prostaglandin synthesis blocking action. During phagocytation of the immune complex by the leukocytes (the immune complex being formed by combining antigen-antibody + complements), prostaglandins are released on two levels : - direct release of prostaglandins as well as other phlogogenic substances (histamine, serotonin and kinins), which are the cause of acute vascular inflammation phenomena. - indirect release of prostaglandins by enzymes such as phospholipase, which acts on the phospholipids in the inflamed cell membrane
• NSAIDs also exert an inhibiting activity on platelet aggregation

Side Effects

Gastro-intestinal disorders : nausea, vomiting, epigastric pain

Contradictions

Absolute : gastroduodenal ulcer, severe hepato-cellular insufficiency, severe renal insufficiency, children under 15 years, pregnancy, (from 6th month) and lactation. Relative : patients receiving oral anticoagulants, combined with other NSAIDs

Observations

• Repeated doses do not lead to any accumulation of diclofenac in the plasma. • When applied to the skin in gel form, the product is absorbed and reaches the plasma and synovial fluids. The concentrations in the fluid and synovial tissue are 40 times higher than the plasma concentrations
• Never combine with other NSAIDs : high risk of ulcer and digestive haemorrhage